ArticleChronic obstructive pulmonary diseases (Miami, Fla.)2021
Increased Health Care Resource Utilization and Costs Associated with Herpes Zoster Among Patients Aged ≥50 Years with Chronic Obstructive Pulmonary Disease in the United States.
Article in Chronic obstructive pulmonary diseases (Miami, Fla.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.
- Global herpes zoster burden in adults with COPD: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- Risk factors for herpes zoster: should people with asthma or COPD be vaccinated?Respiratory research · 2023Pooled it
- The real-world economic impact of herpes zoster disease in patients with selected underlying conditions in Spain.Human vaccines & immunotherapeutics · 2026Observational
- Estimation of Costs Related to the Management of Herpes Zoster and its Complications in Vietnam: A Medical Chart Review.Infectious diseases and therapy · 2026Article
- Divergent Trajectories and Risk Factor Attribution of Chronic Obstructive Pulmonary Disease Burden in China and the United States, 1990-2023: An Age-Period-Cohort Analysis with Projections to 2035 Based on the Global Burden of Disease Study 2023.International journal of chronic obstructive pulmonary disease · 2026Article
- Burden of herpes zoster among patients with systemic lupus erythematosus in the USA.Lupus science & medicine · 2025Article
- Vaccination in Chronic Obstructive Pulmonary Disease.Vaccines · 2025Review
- The Economic Burden of Herpes Zoster in Individuals Aged 50 Years or Older and Those With Underlying Conditions in Italy.Open forum infectious diseases · 2025Article
- Herpes zoster burden in patients with asthma: real-world incidence, healthcare resource utilisation and cost.BMJ open respiratory research · 2024Article
- Burden of Herpes Zoster Among Patients with Psoriasis in the United States.Dermatology and therapy · 2023Article
- Clinical and Economic Burden of Herpes Zoster in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study Using Administrative Claims.Rheumatology and therapy · 2023Article
- Economic and Clinical Burden of Herpes Zoster Among Patients With Inflammatory Bowel Disease in the United States.Crohn's & colitis 360 · 2023Article
- Health Care Professionals' Herpes Zoster Awareness and Vaccine Recommendations for Patients with COPD.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2022Article
- Knowledge and Attitudes Concerning Herpes Zoster among People with COPD: An Interventional Survey Study.Vaccines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
backgroundPatients with chronic obstructive pulmonary disease (COPD) are potentially at increased risk of herpes zoster (HZ). Little is known about the impact of an HZ episode on health care resource utilization (HRU) and costs among patients with COPD.
methodsThis retrospective cohort study of individuals aged ≥50 years in the United States (US) used administrative claims data from Optum's de-identified Clinformatics Data Mart Database for commercially insured and Medicare Advantage members (2013-2018). Two cohorts of patients with COPD, with HZ (COPD+/HZ+) and without HZ (COPD+/HZ-), were identified. All-cause and COPD-related HRU rates and costs (2018 US dollars) were compared between cohorts for up to 12 months of follow-up. Comparisons were controlled for baseline differences through propensity score adjustment.
resultsA total of 3415 COPD+/HZ+ and 35,360 COPD+/HZ- patients (mean ages 73.2 ± 9.0 and 72.4 ± 9.4 years, respectively) were identified. Patients in the COPD+/HZ+ versus COPD+/HZ- cohort had increased use of all-cause (adjusted incidence rate ratio [aIRR] 1.17; 95% confidence interval [CI] 1.14, 1.21) and COPD-related (aIRR 1.27; 95% CI 1.21, 1.34) medical services (both
conclusionsHRU and cost burden is higher in patients with COPD with vs without HZ. These results could help to estimate the potential cost benefits of HZ vaccination among patients with COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.